TCG Crossover Management
Latest statistics and disclosures from TCG Crossover Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, TNGX, CGON, COGT, IMVT, and represent 40.98% of TCG Crossover Management's stock portfolio.
- Added to shares of these 10 stocks: ZLAB (+$117M), AURA (+$68M), TRAX (+$58M), AVTX (+$42M), EDIT (+$36M), PHVS (+$35M), IFRX (+$33M), ALT (+$30M), AKTS (+$23M), FBRX (+$20M).
- Started 12 new stock positions in AKTS, TRAX, IFRX, Jatt Ii Acquisition Corp, EDIT, AURA, FBRX, Research Alliance Corp Iii, ZLAB, ALT. PHVS, EIKN.
- Reduced shares in these 10 stocks: Centessa Pharmaceuticals (-$170M), ABVX (-$63M), TNGX (-$45M), RVMD (-$44M), BHVN (-$42M), FULC (-$40M), ALXO (-$15M), LQDA (-$15M), ARVN (-$14M), LBRX (-$13M).
- Sold out of its positions in Centessa Pharmaceuticals, FULC, LQDA, GPCR, UPB, VTGN, URGN.
- TCG Crossover Management was a net seller of stock by $-17M.
- TCG Crossover Management has $4.2B in assets under management (AUM), dropping by 19.03%.
- Central Index Key (CIK): 0001839948
Tip: Access up to 7 years of quarterly data
Positions held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for TCG Crossover Management
TCG Crossover Management holds 54 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa American Depositary Shares Comm (ABVX) | 19.2 | $801M | -7% | 6.0M | 133.26 |
|
| Tango Therapeutics Comm (TNGX) | 6.8 | $284M | -13% | 9.1M | 31.26 |
|
| Cg Oncology Comm (CGON) | 6.3 | $261M | 3.7M | 71.05 |
|
|
| Cogent Biosciences Comm (COGT) | 4.5 | $188M | 4.9M | 38.70 |
|
|
| Immunovant Comm (IMVT) | 4.1 | $172M | 4.5M | 38.53 |
|
|
| Spyre Therapeutics Comm (SYRE) | 4.1 | $169M | 1.9M | 88.78 |
|
|
| Dianthus Therapeutics Comm (DNTH) | 3.9 | $163M | 1.7M | 97.48 |
|
|
| Mirum Pharmaceuticals Comm (MIRM) | 3.0 | $124M | 1.1M | 117.07 |
|
|
| Zai Lab Ltd- Adrs (ZLAB) | 2.8 | $117M | NEW | 6.1M | 19.00 |
|
| Amylyx Pharmaceuticals Comm (AMLX) | 2.7 | $112M | 6.2M | 17.96 |
|
|
| Monte Rosa Therapeutics Comm (GLUE) | 2.7 | $112M | 4.6M | 24.20 |
|
|
| Biocryst Pharmaceuticals Comm (BCRX) | 2.6 | $110M | 11M | 10.00 |
|
|
| Vor Biopharma Comm (VOR) | 2.5 | $104M | 5.7M | 18.41 |
|
|
| Tyra Biosciences Comm (TYRA) | 2.5 | $104M | 3.2M | 31.94 |
|
|
| Dyne Therapeutics Comm (DYN) | 2.5 | $103M | 4.6M | 22.21 |
|
|
| Disc Medicine Comm (IRON) | 2.4 | $98M | 1.3M | 73.14 |
|
|
| Relay Therapeutics Comm (RLAY) | 1.9 | $80M | 4.3M | 18.71 |
|
|
| Savara Comm (SVRA) | 1.8 | $76M | 12M | 6.16 |
|
|
| Aura Biosciences Comm (AURA) | 1.6 | $68M | NEW | 9.5M | 7.10 |
|
| Revolution Medicines Comm (RVMD) | 1.5 | $64M | -40% | 341k | 187.28 |
|
| First Tracks Biotherapeutics Comm (TRAX) | 1.4 | $58M | NEW | 2.9M | 20.12 |
|
| Kodiak Sciences Comm (KOD) | 1.4 | $56M | 1.4M | 38.96 |
|
|
| Avalo Therapeutics Comm (AVTX) | 1.3 | $56M | +308% | 3.0M | 18.48 |
|
| Lb Pharmaceuticals Comm (LBRX) | 1.1 | $47M | -21% | 1.4M | 32.45 |
|
| Century Therapeutics Comm (IPSC) | 1.0 | $43M | 18M | 2.44 |
|
|
| Tectonic Therapeutic Comm (TECX) | 1.0 | $41M | 1.2M | 34.38 |
|
|
| Xencor Comm (XNCR) | 0.9 | $40M | 2.5M | 16.10 |
|
|
| Surrozen Comm (SRZN) | 0.9 | $38M | 1.5M | 25.95 |
|
|
| Editas Medicine Comm (EDIT) | 0.9 | $36M | NEW | 11M | 3.24 |
|
| Mbx Biosciences Comm (MBX) | 0.9 | $36M | 650k | 55.20 |
|
|
| Pharvaris Bv Comm (PHVS) | 0.8 | $35M | NEW | 1.0M | 34.58 |
|
| Silence Therapeutics Adrs (SLN) | 0.8 | $33M | 3.0M | 10.98 |
|
|
| Inflarx N V Comm (IFRX) | 0.8 | $33M | NEW | 15M | 2.24 |
|
| Altimmune Comm (ALT) | 0.7 | $30M | NEW | 10M | 3.04 |
|
| Janux Therapeutics Comm (JANX) | 0.7 | $28M | 1.8M | 15.36 |
|
|
| Perspective Therapeutics Comm (CATX) | 0.6 | $27M | 7.9M | 3.41 |
|
|
| Agomab Therapeutics Nv Adrs (AGMB) | 0.6 | $27M | 2.1M | 12.98 |
|
|
| Biohaven Comm (BHVN) | 0.6 | $27M | -61% | 1.8M | 14.88 |
|
| Aktis Oncology Comm (AKTS) | 0.5 | $23M | NEW | 697k | 32.23 |
|
| Alector Comm (ALEC) | 0.5 | $20M | 10M | 2.01 |
|
|
| Forte Biosciences Comm (FBRX) | 0.5 | $20M | NEW | 920k | 21.25 |
|
| Monopar Therapeutics Comm (MNPR) | 0.5 | $19M | +53% | 203k | 92.59 |
|
| Ocular Therapeutix Comm (OCUL) | 0.4 | $16M | 1.6M | 9.82 |
|
|
| Adc Therapeutics Sa Comm (ADCT) | 0.3 | $12M | 11M | 1.07 |
|
|
| Alx Oncology Holdings Comm (ALXO) | 0.3 | $12M | -56% | 5.7M | 2.07 |
|
| Entrada Therapeutics Comm (TRDA) | 0.2 | $7.8M | -53% | 1.1M | 7.36 |
|
| Cullinan Therapeutics Comm (CGEM) | 0.2 | $7.4M | 407k | 18.21 |
|
|
| Arvinas Holding Comm (ARVN) | 0.1 | $5.9M | -70% | 707k | 8.31 |
|
| Korro Bio Comm (KRRO) | 0.1 | $5.5M | 416k | 13.18 |
|
|
| Research Alliance Corp Cl A Comm | 0.1 | $5.4M | NEW | 500k | 10.70 |
|
| Leonabio Comm (LONA) | 0.1 | $4.3M | 464k | 9.19 |
|
|
| Jatt Ii Acquisition Corp Comm | 0.1 | $2.3M | NEW | 200k | 11.36 |
|
| Context Therapeutics Comm (CNTX) | 0.0 | $1.5M | 2.7M | 0.55 |
|
|
| Eikon Therapeutics Comm (EIKN) | 0.0 | $495k | NEW | 38k | 13.05 |
|
Past Filings by TCG Crossover Management
SEC 13F filings are viewable for TCG Crossover Management going back to 2021
- TCG Crossover Management 2026 Q2 filed Aug. 14, 2026
- TCG Crossover Management 2026 Q1 filed May 15, 2026
- TCG Crossover Management 2025 Q4 filed Feb. 17, 2026
- TCG Crossover Management 2025 Q3 filed Nov. 17, 2025
- TCG Crossover Management 2025 Q2 filed Aug. 14, 2025
- TCG Crossover Management 2025 Q1 filed May 14, 2025
- TCG Crossover Management 2024 Q4 filed Feb. 14, 2025
- TCG Crossover Management 2024 Q3 filed Nov. 14, 2024
- TCG Crossover Management 2024 Q2 filed Aug. 14, 2024
- TCG Crossover Management 2024 Q1 filed May 15, 2024
- TCG Crossover Management 2023 Q4 filed Feb. 14, 2024
- TCG Crossover Management 2023 Q3 filed Nov. 14, 2023
- TCG Crossover Management 2023 Q2 filed Aug. 14, 2023
- TCG Crossover Management 2023 Q1 filed May 15, 2023
- TCG Crossover Management 2022 Q4 filed Feb. 14, 2023
- TCG Crossover Management 2022 Q3 filed Nov. 14, 2022